Taçoy Gülten, Çengel Atiye, Özkurt Zübeyde Nur, Türkoğlu Sedat
Department of Cardiology, Gazi University Faculty of Medicine, Ankara, Turkey.
Department of Oncology, Gazi University Faculty of Medicine, Ankara, Turkey.
Turk Kardiyol Dern Ars. 2015 Jan;43(1):78-81. doi: 10.5543/tkda.2015.41763.
Pulmonary hypertension (PHT) is a pathological condition determined as an increase in mean pulmonary arterial pressure ≥25 mmHg. Pulmonary arterial hypertension (PAH) is precapillary PHT and a life-threatening disease group which consists of different etiologies with the same pathological and clinical findings, and which is characterized by elevated pulmonary vascular resistance. Dasatinib is a dual Src/Abl kinase inhibitor associated with higher affinity for BCR/ABL kinase than imatinib, and is used in the treatment of chronic myelocytic leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia (ALL). We describe a case with ALL, in whom dasatinib treatment induced PAH, and who recovered with bosentan treatment.
肺动脉高压（PHT）是一种病理状态，定义为平均肺动脉压升高至≥25 mmHg。肺动脉高压（PAH）是毛细血管前性PHT，是一组危及生命的疾病，由具有相同病理和临床特征的不同病因组成，其特征为肺血管阻力升高。达沙替尼是一种双重Src/Abl激酶抑制剂，对BCR/ABL激酶的亲和力高于伊马替尼，用于治疗慢性粒细胞白血病和费城染色体阳性急性淋巴细胞白血病（ALL）。我们报告一例ALL患者，该患者在接受达沙替尼治疗后诱发PAH，经波生坦治疗后康复。
